BridgeBio Pharma Other Non-Current Liabilities 2018-2024 | BBIO
BridgeBio Pharma other non-current liabilities from 2018 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- BridgeBio Pharma other non-current liabilities for the quarter ending September 30, 2024 were $0.000B, a 96.8% decline year-over-year.
- BridgeBio Pharma other non-current liabilities for 2023 were $0.009B, a 64.87% decline from 2022.
- BridgeBio Pharma other non-current liabilities for 2022 were $0.027B, a 20.73% increase from 2021.
- BridgeBio Pharma other non-current liabilities for 2021 were $0.022B, a 131.82% increase from 2020.
BridgeBio Pharma Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$9 |
| 2022 |
$27 |
| 2021 |
$22 |
| 2020 |
$10 |
| 2019 |
$4 |
| 2018 |
$0 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$0 |
| 2024-06-30 |
$0 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$6 |
| 2023-09-30 |
$12 |
| 2023-06-30 |
$13 |
| 2023-03-31 |
$18 |
| 2022-12-31 |
$27 |
| 2022-09-30 |
$28 |
| 2022-06-30 |
$29 |
| 2022-03-31 |
$27 |
| 2021-12-31 |
$22 |
| 2021-09-30 |
$28 |
| 2021-06-30 |
$13 |
| 2021-03-31 |
$12 |
| 2020-12-31 |
$10 |
| 2020-09-30 |
$13 |
| 2020-06-30 |
$9 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.773B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
